AVASTIN Special Drug Use Surveillance (Recurrent, or metastatic carcinoma of the cervix)

AVASTIN Special Drug Use Surveillance (Recurrent, or metastatic carcinoma of the cervix) - AVASTIN Special Drug Use Surveillance(cervical cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022386

Enrollment

130

Registered

2016-06-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All patients(recurrent, or metastatic carcinoma of the cervix) who are scheduled to receive AVASTIN at contracted institutions during this surveillance's enrollment period

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
The incidence of the pelvic part fistulae.	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co. Ltd. Real world data science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results